There is currently no functional cure available to the estimated 296 million people living with Hepatitis B.
iStockVirion Therapeutics has dosed the first patients in a Phase Ib trial investigating VRON-0200 as a functional cure for chronic Hepatitis B virus (HBV) infection.
The first-in-human study (NCT06070051) plans to enrol 48 patients at sites in Hong Kong and New Zealand. Additional sites are planned to open in the US.
The company stated that initial data from the study is expected early next year.
The programme is being conducted with the aid of joint venture partner Ocean Biomedical. The two companies joined forces earlier in October.
VRON-0200 uses one of Virion’s checkpoint modifiers to amplify and broaden a patient’s T cell response against HBV infection. The candidate, which is administered via intramuscular injection, aims to combat immune exhaustion. During preclinical studies, the drug demonstrated an ability to switch on T cells that are not usually activated during a chronic HBV infection.
The World Health Organisation (WHO) estimated that, globally, 296 million people are living with chronic HBV infection. Currently, there is no cure available for the virus, with the standard of care being antiviral therapy – of which there are seven US Food and Drug Administration (FDA)-approved drugs.
By Robert Barrie
Source : Clinical Trials Arena
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
The Rockefeller University: A new mouse model of virus-driven liver cancer may open the door to better diagnosis and treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.